Combinations of beta- 2 -adrenoceptor agonistic benzothiazoloneThe invention provides a pharmaceutical product comprising a first active ingredient which is N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propan amide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a CCR1 antagonist; achemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist which is Aclidinium bromide, Glycopyrrolate, Oxitropium bromide, Pirenzepine, telenzepine, Tiotropium bromide,3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide,3(R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane bromide or (3R)-3-[(2S)-2-cyclopentyl-2-hydroxy-2-thien-2-ylacetoxy]-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]actane bromide; a p38 inhibitor; a PDE inhibitor; a PPARy agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease.Drug products, it comprises the combination of first active component and second active component, described first active component is n-[2-(diethylamino) ethyl]-n-(2-{[2-(4-hydroxyl-2-oxo-2,3-dihydro-1,3-benzothiazole-7-yl) ethyl] amino } ethyl)-3-[2-(naphthalene-1-yl) ethyoxyl] propionic acid amide. or its salt, second active component is selected from:non-steroidal glucocoricoid receptor (gr receptor) agonist;antioxidant;the ccr1 antagonist;chemokine antagonists (non-ccr1 antagonist);17-hydroxy-11-dehydrocorticosterone;the crth2 antagonist;the dp1 antagonist;the histone deacetylase inducer;the ikk2 inhibitor;the cox inhibitor;lipoxidase inhibitor;ltra;the mpo inhibitor;muscarinic receptor antagonist, it is ah 's bromine ammonium, glycopyrronium bromide, oxitropium bromide, pirenzepine, telenzepine, tiotropium bromide, 3 (r)-(2-hydroxyl-2,2-two (thiophene-2-yl) acetoxyl group)-1-(3-phenoxy propyl)-1-nitrogen bicyclo-[2.2.2] octane bromide, 3 (r)-1-phenethyl-3-(9h-xanthene-9-ketonic oxygen base)-1-nitrogen bicyclo-[2.2.2] octane bromide or (3r)-3-[(2s)-2-cyclopenta-2-hydroxyl-2-(thiophene-2-yl) acetoxyl group]-1-(2-phenoxy group ethyl)-1-nitrogen bicyclo-[2.2.2] octane bromide;the p38 inhibitor;the pde inhibitor;the ppar gamma agonist;protease inhibitor;inhibin;the thromboxane antagonist;vasodilator; orenac blocker (epithelium sodium channel blockers).
베타­２­아드레날린성 수용체 효능성 벤조티아졸론의 조합물본 발명은 제1 활성 성분으로서 N-[2-(디에틸아미노)에틸]-N-(2-{[2-(4-히드록시-2-옥소-2,3-디히드로-1,3-벤조티아졸-7-일)에틸]아미노}에틸)-3-[2-(1-나프틸)에톡시]프로판아미드 또는 그의 염, 및 제2 활성 성분으로서 비스테로이드성 글루코코르티코이드 수용체 (GR 수용체) 효능제; 항산화제; CCR1 길항제; 케모카인 길항제 (CCR1이 아님); 코르티코스테로이드; CRTh2 길항제; DP1 길항제; 히스톤 디아세틸라제 유도제; IKK2 억제제; COX 억제제; 리폭시게나제 억제제; 류코트리엔 수용체 길항제; MPO 억제제; 아클리디늄 브로마이드, 글리코피롤레이트, 옥시트로퓸 브로마이드, 피렌제핀, 텔렌제핀, 티오트로퓸 브로마이드, 3(R)-(2-히드록시-2,2-디티엔-2-일아세톡시)-1-(3-페녹시프로필)-1-아조니아비시클로[2.2.2]옥탄 브로마이드, 3(R)-1-페네틸-3-(9H-크산텐-9-카르보닐옥시)-1-아조니아비시클로[2.2.2]옥탄 브로마이드 또는 (3R)-3-[(2S)-2-시클로펜틸-2-히드록시-2-티엔-2-일아세톡시]-1-(2-페녹시에틸)-1-아조니아비시클로[2.2.2]악탄 브로마이드인 무스카린 길항제; p38 억제제; PDE 억제제; PPARγ 효능제; 프로테아제 억제제; 스타틴; 트롬복산 길항제; 혈관확장제; 또는 ENAC 차단제 (상피 나트륨 채널 차단제)로부터 선택된 것을 포함하는 제약 생성물, 및 호흡기 질환의 치료에 있어서의 그의 용도를 제공한다.제1 활성 성분으로서 N-[2-(디에틸아미노)에틸]-N-(2-{[2-(4-히드록시-2-옥소-2,3-디히드로-1,3-벤조티아졸-7-일)에틸]아미노}에틸)-3-[2-(1-나프틸)에톡시]프로판아미드 또는 그의 염, 및 제2 활성 성분으로서 하기로부터 선택된 것을 조합물로 포함하는 제약 생성물: 비스테로이드성 글루코코르티코이드 수용체 (GR 수용체) 효능제; 항산화제; CCR1 길항제; 케모카인 길항제 (CCR1이 아님); 코르티코스테로이드; CRTh2 길항제; DP1 길항제; 히스톤 디아세틸라제 유도제; IKK2 억제제; COX 억제제; 리폭시게나제 억제제; 류코트리엔 수용체 길항제; MPO 억제제; 아클리디늄 브로마이드, 글리코피롤레이트, 옥시트로퓸 브로마이드, 피렌제핀, 텔렌제핀, 티오트로퓸 브로마이드, 3(R)-(2-히드록시-2,2-디티엔-2-일아세톡시)-1-(3-페녹시프로필)-1-아조니아비시클로[2.2.2]옥탄 브로마이드, 3(R)-1-페네틸-3-(9H-크산텐-9-카르보닐옥시)-1-아조니아비시클로[2.2.2]옥탄 브로마이드 또는 (3R)-3-[(2S)-2-시클로펜틸-2-히드록시-2-티엔-2-일아세톡시]-1-(2-페녹시에틸)-1-아조니아비시클로[2.2.2]악탄 브로마이드인 무스카린 길항제; p38 억제제; PDE 억제제; PPARγ 효능제; 프로테아제 억제제; 스타틴; 트롬복산 길항제; 혈관확장제; 또는 ENAC 차단제 (상피 나트륨 채널 차단제).